Menu
Recruiting NCT07184203

Comparison Between Continuous and Pulse Itraconazole in Tinea Capitis in Children

No phase Interventional Tinea Capitis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Itraconazole (ITZ).
Who it may be relevant to
Registry conditions: Tinea Capitis. Basic parameters: 5 years — 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Comparative Clinicomycologic and Dermoscopic Study Between Daily and Pulse Therapy of Oral Itraconazole in Tinea Capitis in Children

Overview

A study to compare the efficacy of daily therapy versus pulse therapy of oral itraconazole in the treatment of tinea capitis in children based on clinical, mycological and dermoscopic evaluation.

Interventions

  • Drug Itraconazole (ITZ)
    therapy for tinea capitis orally

Primary outcome measures

  • improvement of tinea capitis [Time frame: 3 months]

Eligibility criteria

Inclusion criteria

  • Tinea capitis patients with ages ranging from 5 to 18 year

Exclusion criteria

  • Patients with contraindications to itraconazole
  • Patients with associated scalp disease.
  • Patients weighing less than 20 Kg.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Faculty of Medicine — Alexandria

Identifiers

NCT: NCT07184203 · 0108853

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗